Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05045950 · ClinicalTrials.gov registry record · Phase 2
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
A Phase 2 study of Brain Metastases, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 2
- Study locations
NCT05045950 is a Phase 2 study of Brain Metastases that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 53 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05045950, a Phase 2 study of Brain Metastases, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 2
- Study locations
Study Summary
Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
Conditions Studied
Interventions
- DRUG Memantine -Twice Daily or Extended Release
- RADIATION WBRT utilizing the PRDR technique
Study Locations (2)
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
- Clement J. Zablocki Veterans Affairs Medical Center - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05045950
The ClinicalTrials.gov registry entry for NCT05045950 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which Memantine -Twice Daily or Extended Release is the first listed.
NCT05045950 reports 2 study locations spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05045950 about?
NCT05045950 is a clinical study titled "Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique". Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
What is the current status of trial NCT05045950?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2021-11-17. Estimated completion is 2029-05.
What conditions does trial NCT05045950 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT05045950?
The interventions under investigation include: Memantine -Twice Daily or Extended Release (DRUG), WBRT utilizing the PRDR technique (RADIATION).
Who is sponsoring clinical trial NCT05045950?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05045950 being conducted?
This trial has 2 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.